Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

XenoPort, Inc. (XNPT) - Financial and Strategic SWOT Analysis Review

VIEWS: 15 PAGES: 40

XenoPort, Inc. (XenoPort) is a bio-pharmaceutical company with focus on the development and commercialization of internally discovered product candidates for the treatment of neurological disorders. The company develops prodrugs which are created by modification of chemical structure of existing drugs in the market. The company's product pipeline include, XP21279, XP23829 and arbaclofen placarbil for the treatment of gastroesophageal reflux disease, migraine headaches, restless legs syndrome (RLS), neuropathic pain, spasticity related to spinal cord injury and Parkinson’s disease. Gabapentin enacarbil is the company's first product to be approved for commercialization in the US and Japan for the treatment of Restless Legs Syndrome. The company partners with other pharmaceutical companies for the development and commercialization of its drugs which include, GlaxoSmithKline and Astellas Pharma Inc. Xenoport is headquartered in Santa Clara, California, the US. The company strategically intends to seek partnerships for the development and commercialization of its pipeline drugs.

More Info
  • pg 1
									         XenoPort, Inc. (XNPT) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDPH8427FSA                                                                                           Publication Date: AUG 2012

          3410 Central Expressway                            Phone              +1 408 6167200                  Revenue          43.5 (million USD)
          Santa Clara, CA                                    Fax                +1 302 5313150                  Net Profit       -33.38 (million USD)
          95051                                              Website            www.xenoport.com                Employees        112
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           XNPT [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       XenoPort, Inc. (XenoPort) is a bio-pharmaceutical company with focus on the development and commercialization of internally
       discovered product candidates for the treatment of neurological disorders. The company develops prodrugs which are created by
       modification of chemical structure of existing drugs in the market. The company's product pipeline include, XP21279, XP23829
       and arbaclofen placarbil for the treatment of gastroesophageal reflux disease, migraine headaches, restless legs syndrome
       (RLS), neuropathic pain, spasticity related to spinal cord injury and Parkinson’s disease.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      XenoPort, Inc., SWOT Analysis
         Ronald W. Barrett, Ph.D.            Chief Executive Officer                  Strengths                              Weaknesses
         William J. Rieflin                  Director
                                                                                      Strong Research and                    Involvement in Litigations
         Paul L. Berns                       Director                                 Development Activities
                                                                                                                             Weak Profitability Position
         Dennis M. Fenton, Ph.D.             Director
                                                                                      Technological Base
         John G. Freund, M.D                 Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Market Potential – CNS                 Competitive Landscape
         XenoPort, Inc.                                                               Therapy
                                                                                                                             Stringent Government
        Share Price (USD) as on 02-Aug-                                  7.44         Demographic Trends                     Regulations
        2012
        EPS (USD)                                                       -0.94
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        Market Cap (million USD)                                         210         GlobalData

        Enterprise Value (million USD)                                   197
        Shares Outstanding (million)                                       36
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Jun 04, 2012         XenoPort Names Vincent Angotti As COO
                                                                                      May 02, 2012         XenoPort Reports Revenue Of $10.4m In Q1
                                                                                                           2012
                                                                                      Feb 14, 2012         XenoPort Reports Revenue Of $5.4m In Q4
                                                                                                           2011
                                                                                      Nov 02, 2011         XenoPort Reports Q3 2011 Results
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData



       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




XenoPort, Inc. (XNPT) - Financial and Strategic SWOT Analysis                                                                    Reference Code: GDPH8427FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 3
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       XenoPort, Inc. - Key Facts.................................................................................................................................................................. 5
       XenoPort, Inc. - Key Employees......................................................................................................................................................... 6
       XenoPort, Inc. - Key Employee Biographies....................................................................................................................................... 7
       XenoPort, Inc. - Major Products and Services .................................................................................................................................... 8
       XenoPort, Inc. - Pharmaceutical Pipeline Products Data ................................................................................................................... 9
          XenoPort, Inc., Pipeline Products by Therapy Area ........................................................................................................................ 9
          XenoPort, Inc., Pipeline Products by Development Phase ........................................................................................................... 10
       XenoPort, Inc. - History .................................................................................................................................................................... 12
       XenoPort, Inc. - Company Statement ............................................................................................................................................... 14
       XenoPort, Inc. - Locations And Subsidiaries .................................................................................................................................... 16
          Head Office ................................................................................................................................................................................... 16
       Section 2 – Company Analysis ......................................................................................................................................................... 17
       XenoPort, Inc. - Business Description .............................................................................................................................................. 17
       XenoPort, Inc. - Corporate Strategy ................................................................................................................................................. 18
       XenoPort, Inc. - SWOT Analysis ...................................................................................................................................................... 19
          SWOT Analysis - Overview........................................................................................................................................................... 19
          XenoPort, Inc. - Strengths............................................................................................................................................................. 19
             Strength - Strong Research and Development Activities........................................................................................................... 19
             Strength - Technological Base .................................................................................................................................................. 19
             Strength - Strong Intellectual Property Portfolio ........................................................................................................................ 19
          XenoPort, Inc. - Weaknesses ....................................................................................................................................................... 19
             Weakness - Involvement in Litigations ...................................................................................................................................... 19
             Weakness - Weak Profitability Position ..................................................................................................................................... 20
          XenoPort, Inc. - Opportunities....................................................................................................................................................... 20
             Opportunity - Market Potential – CNS Therapy ......................................................................................................................... 20
             Opportunity - Demographic Trends ........................................................................................................................................... 20
             Opportunity - Emerging Markets ............................................................................................................................................... 20
          XenoPort, Inc. - Threats ................................................................................................................................................................ 21
             Threat - Competitive Landscape ............................................................................................................................................... 21
             Threat - Stringent Government Regulations .............................................................................................................................. 21
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 21
       XenoPort, Inc. - Key Competitors ..................................................................................................................................................... 22
       Section 3 – Company Financial Ratios ............................................................................................................................................. 23
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 23
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 23
       Performance Chart ........................................................................................................................................................................... 25
       Financial Performance...................................................................................................................................................................... 25
       Financial Ratios - Interim Ratios....................................................................................................................................................... 26
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 27
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 28
          XenoPort, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 ..................................................................... 28


XenoPort, Inc. (XNPT) - Financial and Strategic SWOT Analysis                                                                                                    Reference Code: GDPH8427FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          XenoPort, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 ..................................................................... 29
       XenoPort, Inc., Recent Deals Summary ........................................................................................................................................... 30
       Section 5 – Company’s Recent Developments ........................................................................................................
								
To top